Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 15, 2019 - Issue 3
Submit an article Journal homepage
1,907
Views
5
CrossRef citations to date
0
Altmetric
Research Paper

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

Beate Schmoele-ThomaPfizer Vaccine Clinical Research and Development, Pfizer Pharma GmbH, Berlin, GermanyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-4632-357XView further author information
ORCID Icon,
Martin van CleeffTriangle Medical Research Associates, Raleigh, NC, USAView further author information
,
Richard N. GreenbergPfizer Vaccine Clinical Research and Development, Pearl River, NY, USAView further author information
,
Alejandra GurtmanPfizer Vaccines Research, Pearl River, NY, USAView further author information
,
Thomas R. JonesPfizer Vaccines Research, Pearl River, NY, USAView further author information
,
Vani SundaraiyerSyneos Health, Princeton, NJ, USAView further author information
,
William C. GruberPfizer Vaccines Research, Pearl River, NY, USAView further author information
&
Daniel A. ScottPfizer Vaccines Research, Pearl River, NY, USAView further author information
 show all
Pages 575-583 | Received 06 Feb 2018, Accepted 13 Oct 2018, Published online: 16 Jan 2019

References

  • Butler JC, Schuchat A. Epidemiology of pneumococcal infections in the elderly. Drugs Aging. 1999;15(suppl 1):11–19.
  • Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, Schouls LM, Sanders EA, van der Ende A. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27(17):2394–2401. doi:10.1016/j.vaccine.2009.01.127.
  • Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729–1735.
  • Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. [ accessed 2017 Sept 18]. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html.
  • Ricketson LJ, Nettel-Aguirre A, Vanderkooi OG, Laupland KB, Kellner JD. Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLoS ONE. 2013;8(10):e71924. doi:10.1371/journal.pone.0071924.
  • Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K; Competence Network for Community-Acquired Pneumonia Study Group. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008;32(1):139–146. doi:10.1183/09031936.00092507.
  • Kyaw MH, Rose CE Jr., Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192(3):377–386. JID34127 [pii]. doi:10.1086/431521..
  • Verhaegen J, Flamaing J, De Backer W, Delaere B, Van Herck K, Surmont F, Van Laethem Y, Van Damme P, Peetermans W. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011. Euro Surveill. 2014;19(31):14–22.
  • Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944–947. doi:10.15585/mmwr.mm6434a4.
  • Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine. 2014;32(20):2364–2374. doi:10.1016/j.vaccine.2014.02.002.
  • Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31(35):3585–3593. doi:10.1016/j.vaccine.2013.05.010.
  • Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31(35):3594–3602. doi:10.1016/j.vaccine.2013.04.084.
  • Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun. 1997;65(1):242–247.
  • Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 2009;49(9):1318–1325. doi:10.1086/606046.
  • Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis. 2009;49(2):241–248. doi:10.1086/599824.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.